Suppr超能文献

糖尿病视网膜病变的相关效用:来自加拿大样本的结果

Utilities associated with diabetic retinopathy: results from a Canadian sample.

作者信息

Sharma S, Oliver-Fernandez A, Bakal J, Hollands H, Brown G C, Brown M M

机构信息

The Cost-Effective Ocular Health Policy Unit, Queen's University, Hotel Dieu Hospital, Kingston, ON, Canada.

出版信息

Br J Ophthalmol. 2003 Mar;87(3):259-61. doi: 10.1136/bjo.87.3.259.

Abstract

BACKGROUND/AIMS: To report patient based utilities, using the time trade-off technique, associated with visual loss secondary to diabetic retinopathy in a sample of Canadian patients. In addition, to compare these utility values with a sample collected in a similar manner in a tertiary care practice in the United States.

METHODS

A cross sectional study of eligible patients with diabetic retinopathy presenting to a tertiary facility was performed. Demographic and clinical variables (including Snellen visual acuity), and utilities were collected both through chart review and standardised interviews with diabetic patients.

RESULTS

221 patients with diabetic retinopathy were eligible for this study and completed the interview. The mean age was 63.5 (SD 12.5) years, and 48.4% were female. Over 35% of the sample had visual acuity in the affected eye of 6/60 or worse. The mean utility for the sample was 0.79 (SD 0.23). The mean utility from this sample did not differ significantly from that obtained from a series of patients with diabetic retinopathy who were referred to a tertiary facility in the United States (mean 0.77, SD 0.21, p=0.313). Our cross border comparison had a power of 95% to detect a difference in utility of 0.1 between the two groups.

CONCLUSION

On average, Canadian patients with diabetic retinopathy were willing to trade off over 20% of their remaining lifespan in order to eliminate their ocular disease. The mean utility obtained from our sample of Canadian patients with diabetic retinopathy was not statistically different from that obtained from a similar sample of American patients.

摘要

背景/目的:采用时间权衡技术报告加拿大患者样本中与糖尿病性视网膜病变继发视力丧失相关的基于患者的效用值。此外,将这些效用值与在美国一家三级医疗中心以类似方式收集的样本进行比较。

方法

对就诊于三级医疗机构的符合条件的糖尿病性视网膜病变患者进行横断面研究。通过病历审查和对糖尿病患者的标准化访谈收集人口统计学和临床变量(包括斯内伦视力)及效用值。

结果

221例糖尿病性视网膜病变患者符合本研究条件并完成访谈。平均年龄为63.5(标准差12.5)岁,48.4%为女性。超过35%的样本患眼视力为6/60或更差。样本的平均效用值为0.79(标准差0.23)。该样本的平均效用值与从美国一家三级医疗机构转诊的一系列糖尿病性视网膜病变患者获得的平均效用值(0.77,标准差0.21,p = 0.313)无显著差异。我们的跨境比较有95%的把握检测出两组效用值相差0.1。

结论

平均而言,加拿大糖尿病性视网膜病变患者愿意牺牲超过20%的剩余寿命以消除眼部疾病。我们加拿大糖尿病性视网膜病变患者样本获得的平均效用值与美国类似患者样本获得的平均效用值无统计学差异。

相似文献

1
Utilities associated with diabetic retinopathy: results from a Canadian sample.
Br J Ophthalmol. 2003 Mar;87(3):259-61. doi: 10.1136/bjo.87.3.259.
2
Utility values and diabetic retinopathy.
Am J Ophthalmol. 1999 Sep;128(3):324-30. doi: 10.1016/s0002-9394(99)00146-4.
3
Disparities between Ophthalmologists and Patients in Estimating Quality of Life Associated with Diabetic Retinopathy.
PLoS One. 2015 Dec 2;10(12):e0143678. doi: 10.1371/journal.pone.0143678. eCollection 2015.
5
Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration.
Arch Ophthalmol. 2002 Apr;120(4):481-4. doi: 10.1001/archopht.120.4.481.
6
The impact of anchor point on utilities for 5 common ophthalmic diseases.
Ophthalmology. 2008 May;115(5):898-903.e4. doi: 10.1016/j.ophtha.2007.06.008. Epub 2007 Sep 12.
7
TTO utility scores measure quality of life in patients with visual morbidity due to diabetic retinopathy or ARMD.
Ophthalmic Epidemiol. 2004 Feb;11(1):43-51. doi: 10.1076/opep.11.1.43.26436.
8
Health utility values associated with diabetic retinopathy.
Diabet Med. 2008 May;25(5):618-24. doi: 10.1111/j.1464-5491.2008.02430.x. Epub 2008 Mar 13.
9
Reliability of the time trade-off technique of utility assessment in patients with retinal disease.
Can J Ophthalmol. 2001 Jun;36(4):202-9. doi: 10.1016/s0008-4182(01)80041-7.
10
Patient preferences for diabetic retinopathy health States.
Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3387-94. doi: 10.1167/iovs.09-4194. Epub 2010 Jan 6.

引用本文的文献

1
Diabetic retinal disease.
Nat Rev Dis Primers. 2025 Aug 28;11(1):62. doi: 10.1038/s41572-025-00646-x.
3
Measuring Quality of Life in Diabetic Retinal Disease: A Narrative Review of Available Patient-Reported Outcome Measures.
Ophthalmol Sci. 2023 Aug 9;4(2):100378. doi: 10.1016/j.xops.2023.100378. eCollection 2024 Mar-Apr.
4
A systematic review of economic evaluations for -mediated inherited retinal disease including HTA assessment of broader value.
Int J Technol Assess Health Care. 2023 Jun 14;39(1):e38. doi: 10.1017/S0266462323000326.
5
Assessing patient perception of risk in ocular stem cell therapies.
Stem Cell Reports. 2021 Oct 12;16(10):2415-2421. doi: 10.1016/j.stemcr.2021.09.001. Epub 2021 Sep 30.
6
Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal Disease.
JAMA Ophthalmol. 2019 Oct 1;137(10):1115-1123. doi: 10.1001/jamaophthalmol.2019.2512.
9
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.
Int J Retina Vitreous. 2017 Feb 13;3:5. doi: 10.1186/s40942-016-0058-3. eCollection 2017.
10
Disparities between Ophthalmologists and Patients in Estimating Quality of Life Associated with Diabetic Retinopathy.
PLoS One. 2015 Dec 2;10(12):e0143678. doi: 10.1371/journal.pone.0143678. eCollection 2015.

本文引用的文献

2
Incremental cost-effectiveness of initial cataract surgery.
Ophthalmology. 2002 Mar;109(3):606-12; discussion 612-3. doi: 10.1016/s0161-6420(01)00971-x.
3
A cost-utility analysis of interventions for severe proliferative vitreoretinopathy.
Am J Ophthalmol. 2002 Mar;133(3):365-72. doi: 10.1016/s0002-9394(01)01423-4.
4
Improvement in quality of life from photodynamic therapy: a Canadian perspective.
Can J Ophthalmol. 2001 Oct;36(6):332-8. doi: 10.1016/s0008-4182(01)80120-4.
6
Reliability of the time trade-off technique of utility assessment in patients with retinal disease.
Can J Ophthalmol. 2001 Jun;36(4):202-9. doi: 10.1016/s0008-4182(01)80041-7.
8
Converting visual acuity to utilities.
Can J Ophthalmol. 2000 Aug;35(5):267-72. doi: 10.1016/s0008-4182(00)80077-0.
10
Incremental cost effectiveness of laser photocoagulation for subfoveal choroidal neovascularization.
Ophthalmology. 2000 Jul;107(7):1374-80. doi: 10.1016/s0161-6420(00)00169-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验